TRIVENI
LIVE

Serial Number

97810745

Owner

TRIVENI BIO, INC.

Attorney

Christina M. Licursi

Filing Date

Feb 24, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TRIVENI Trademark

Serial Number: 97810745

TRIVENI is a trademark filed by TRIVENI BIO, INC. on February 24, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

TRIVENI BIO, INC.

100 BEAVER STREET, SUITE 307
WALTHAM, MA 02453

Entity Type: 03

Amagma, Inc.

100 Beaver Street, Suite 307
Waltham, MA 02453

Entity Type: 03

Trademark Details

Filing Date

February 24, 2023

Registration Date

Not Registered

Published for Opposition

October 15, 2024

Goods & Services

Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and discovery; research and analysis services using machine learning analytics relating to drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents; research services in the fields of genomic analysis; scientific research, namely, genomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; scientific research, namely, DNA analysis and sequencing services for scientific and research purposes; scientific research, development and scientific research consultancy in the field of genomics; medical research, namely, compiling data for research purposes in the field of genomics

Pharmaceutical, therapeutic and biopharmaceutical agents for treatment of immunological and inflammatory disorders; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for treatment of genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune/autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; biological preparations, namely, antibodies for medical purposes

Filing History

TEAS STATEMENT OF USE RECEIVED
May 26, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2025 EXRA
SOU EXTENSION 2 GRANTED
Oct 1, 2025 EX2G
SOU EXTENSION 2 FILED
Oct 1, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 1, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
May 27, 2025 EX1G
SOU EXTENSION 1 FILED
May 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
May 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 3, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 8, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 8, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 8, 2024 CNRT
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 4, 2024 GNFN
FINAL REFUSAL E-MAILED
Jun 4, 2024 GNFR
FINAL REFUSAL WRITTEN
Jun 4, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 29, 2024 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 17, 2024 ASGN
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 5, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 5, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 30, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 30, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 30, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 25, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2023 NWOS